Lin Zhongjing, Hu Qiwei, Wu Yanlin, Xu Jianmin, Zhang Qiong
Department of Ophthalmology, Ruijin Hospital Affiliated Medical School, Shanghai Jiaotong University, 197 Ruijin Er Road, Shanghai, 200025, China.
BMC Ophthalmol. 2019 Jan 15;19(1):18. doi: 10.1186/s12886-019-1035-z.
There is no consensus for the standard treatment of retinal arterial macroaneurysm (RAM). Intravitreal anti-vascular endothelium growth factor (anti-VEGF) is an alternative treatment option for RAM. The purpose of this study is to describe the clinical efficacy of intravitreal ranibizumab or intravitreal conbercept for retinal arterial macroaneurysm.
Three cases that presented with symptomatic RAM were treated with intravitreal anti-VEGF agents. Two eyes received two intravitreal ranibizumab injections with a time interval of one month and completed a one-year follow-up, while one eye only received one intravitreal conbercept injection and was followed up for six months. Both the retinal thickness and the visual acuity were significantly improved at the final clinic visit. The macular hemorrhage and edema were resolved. There were no ocular or systemic side effects.
Intravitreal ranibizumab or conbercept might be used as a therapeutic option for symptomatic retinal arterial macroaneurysm patients. Anti-VEGF therapy should be further investigated in a larger series with longer follow-up for this disease profile.
视网膜动脉大动脉瘤（RAM）的标准治疗尚无共识。玻璃体内抗血管内皮生长因子（抗VEGF）是RAM的一种替代治疗选择。本研究的目的是描述玻璃体内注射雷珠单抗或康柏西普治疗视网膜动脉大动脉瘤的临床疗效。
3例有症状的RAM患者接受了玻璃体内抗VEGF药物治疗。2只眼接受了2次玻璃体内雷珠单抗注射，时间间隔为1个月，并完成了1年的随访，而1只眼仅接受了1次玻璃体内康柏西普注射，并随访了6个月。在最后一次临床就诊时，视网膜厚度和视力均显著改善。黄斑出血和水肿消退。未出现眼部或全身副作用。
玻璃体内注射雷珠单抗或康柏西普可作为有症状的视网膜动脉大动脉瘤患者的一种治疗选择。对于这种疾病，应在更大规模、更长随访时间的系列研究中进一步研究抗VEGF治疗。
